

Round Table Discussion: Clinical Applications of Hyperglycosylated hCG in Diseases of Pregnancy, Cancer & Prenatal Diagnosis

Introductory remarks

Ulf-Håkan Stenman, Department of Clinical Chemistry, Helsinki University Central Hospital, FIN-00029 HUS, Finland

Hyperglycosylated hCG is presently defined as hCG reacting with the monoclonal antibody B152, the epitope of which comprises the core 2 *o*-glycan linked to Ser132 on hCG β and surrounding peptide moieties. Other forms of aberrantly glycosylated hCG are expressed by some cancers and these may be recognized to variable degree by B152. Assays based on B152 have been shown to be of potential utility for detection of aberrant early pregnancy, Down's syndrome, and hCG-producing cancers. The aim of the round table discussion is to define what is presently known about the clinical utility of assays for hyperglycosylated hCG and to evaluate what needs to be studied in order to establish whether these assays provide clinical information additional to that provided by presently used assays.